| Literature DB >> 27110936 |
Cory M Resnick1, Pouya M Vakilian2, Micheál Breen3, David Zurakowski3, Paul Caruso4, Lauren Henderson3, Peter A Nigrovic5, Leonard B Kaban6, Zachary S Peacock6.
Abstract
OBJECTIVE: Juvenile idiopathic arthritis (JIA) frequently affects the temporomandibular joints (TMJs) and is often undetected by history, examination, and plain imaging. Qualitative assessment of gadolinium-enhanced magnetic resonance images (MRIs) is currently the standard for diagnosis of TMJ synovitis associated with JIA. The purpose of this study is to apply a quantitative analysis of synovial enhancement to MRIs of patients with and without JIA to establish a disease threshold and sensitivity and specificity for the technique.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27110936 PMCID: PMC5573997 DOI: 10.1002/acr.22911
Source DB: PubMed Journal: Arthritis Care Res (Hoboken) ISSN: 2151-464X Impact factor: 4.794
Figure 1T1‐weighted gadolinium‐enhanced magnetic resonance image (coronal view) of a healthy 10‐year‐old boy without temporomandibular joint (TMJ) pathology. The inferior (arrowheads) and superior (arrows) joint spaces are shown bilaterally. Regions of interest used to calculate the enhancement ratio (ER) are indicated at the right inferior TMJ space (circle) and left longus capitis muscle (ellipse). ER = 1.33 (left) and 1.21 (right).
Figure 2T1‐weighted gadolinium‐enhanced magnetic resonance image (coronal view) of a 14‐year‐old boy with juvenile idiopathic arthritis and inflammatory temporomandibular joint (TMJ) arthritis. The superior (arrows) and inferior (arrowheads) joint spaces are shown bilaterally. Regions of interest used to calculate the enhancement ratio (ER) are indicated at the inferior right TMJ space (circle) and left longus capitis muscle (ellipse). Qualitative radiologist interpretation noted moderate to severe bilateral TMJ synovial enhancement. Quantitative analysis found ER = 2.48 (right) and 2.52 (left).
Sample characteristicsa
| JIA group | |
| Sample size, no. | 74 |
| Total MRIs | 114 |
| Total joints | 211 |
| Age at JIA diagnosis, mean ± SD years | 7.24 ± 4.24 |
| Age at MRI, mean ± SD years | 13.19 ± 3.78 |
| Female | 61 (82) |
| Family autoimmune disease history | 48 (65) |
| JIA subtype | |
| Psoriatic | 27 (36) |
| Oligoarticular | 22 (30) |
| Polyarticular | 19 (26) |
| Systemic | 6 (8) |
| Medication exposure | |
| Methotrexate | 25 (34) |
| Nonsteroidal antiinflammatory drugs | 14 (19) |
| Adalimumab | 10 (14) |
| Leflunomide | 7 (9) |
| Etanercept | 7 (9) |
| Sulfasalazine | 5 (7) |
| Infliximab | 4 (5) |
| Prednisone | 2 (3) |
| Control group | |
| Sample size, no. | 71 |
| Total MRIs | 71 |
| Total joints | 142 |
| Age at MRI, mean ± SD years | 11.4 ± 3.5 |
| Female | 38 (54) |
| MRI type | |
| Temporal bone | 60 (85) |
| Optic nerve | 11 (15) |
| Indication for MRI | |
| Sensorineural hearing loss | 27 (38) |
| Cholesteatoma | 13 (18) |
| Facial nerve palsy | 11 (16) |
| Otalgia | 9 (13) |
| Optic neuropathy | 8 (11) |
| Papilledema | 3 (4) |
Values are the no. (%) unless otherwise indicated. JIA = juvenile idiopathic arthritis; MRI = magnetic resonance imaging.
Analysis of synovial enhancement ratio to study variables for control and JIA groupsa
| Variable | Mean ± SD enhancement ratio |
|
|---|---|---|
| Control group | ||
| Age | 0.735 | |
| Sex | 0.447 | |
| Female | 1.24 ± 0.14 | |
| Male | 1.25 ± 0.15 | |
| Antiinflammatory medication | 0.183 | |
| Yes | 1.29 ± 0.19 | |
| No | 1.30 ± 0.17 | |
| MRI type | 0.403 | |
| Temporal bone | 1.27 ± 0.16 | |
| Optic nerve | 1.25 ± 0.16 | |
| MRI indication | 0.850 | |
| Sensorineural hearing loss | 1.29 ± 0.14 | |
| Cholesteatoma | 1.30 ± 0.11 | |
| Facial nerve palsy | 1.29 ± 0.13 | |
| Otalgia | 1.28 ± 0.11 | |
| Optic neuropathy | 1.27 ± 0.17 | |
| Papilledema | 1.26 ± 0.17 | |
| JIA group | ||
| Age | 0.354 | |
| Sex | 0.045 | |
| Female | ||
| Male | ||
| Family history of autoimmune disease | 0.093 | |
| Positive | 2.51 ± 0.79 | |
| Negative | 2.53 ± 0.80 | |
| JIA subtype | 0.500 | |
| Psoriatic | 2.42 ± 0.81 | |
| Oligoarticular | 2.55 ± 0.84 | |
| Polyarticular | 2.58 ± 0.79 | |
| Systemic | 2.70 ± 0.63 | |
| Medication | ||
| Methotrexate | 2.45 ± 0.8 | 0.029 |
| Nonsteroidal antiinflammatory drugs | 2.49 ± 0.75 | 0.018 |
| Adalimumab | 2.62 ± 0.82 | 0.620 |
| Leflunomide | 2.24 ± 0.71 | 0.014 |
| Etanercept | 2.59 ± 0.86 | 0.254 |
| Sulfasalazine | 3.01 ± 0.87 | 0.485 |
| Infliximab | 2.43 ± 0.70 | 0.035 |
| Prednisone | 2.03 ± 0.53 | 0.041 |
JIA = juvenile idiopathic arthritis; MRI = magnetic resonance imaging.
Statistically significant.
Figure 3Receiver operating characteristic curve for synovial enhancement ratio (ER), indicating an area under the curve (AUC) of 0.959 (95% confidence interval [95% CI] 0.937, 0.980; P < 0.001), sensitivity of 91%, and specificity of 96%, for an optimal threshold value of ER = 1.55.
Figure 4Probability curve derived from logistic regression analysis, demonstrating a high likelihood of juvenile idiopathic arthritis (JIA) for an enhancement ratio ≥1.55 (65%), 1.70 (85%), 1.90 (96%), and 2.00 (98%).